Payment overview · 2025
General Payments
$854.88
30 reported records · 14 companies
Healthcare provider profile · identity verified
Shamsad Begum, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WEST PALM BEACH, FL · NPI 1386629673
Verified facts
What the public records show
CMS Open Payments records show Shamsad Begum, MD received $854.88 in general payments during 2025 across 30 reported records.
ACADIA Pharmaceuticals Inc accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Eliquis, Jardiance, Ozempic, Rexulti, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 440 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $150.42 | 17.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.34 | 16.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $118.38 | 13.8% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $113.00 | 13.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $70.47 | 8.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $53.26 | 6.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.35 | 5.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 4.4% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $24.47 | 2.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.34 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.19 | 2.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.89 | 2.2% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$18.19 | 2.1% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $17.88 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.18 | 28 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $150.42 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.34 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $137.27 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $113.00 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.64 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 440 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
440 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
113 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 24 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 848 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 698 | 144 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 550 | 76 |
| Gabapentin | Gabapentin | 532 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 489 | 92 |
| Metformin Hcl | Metformin Hcl | 453 | 120 |
| Furosemide | Furosemide | 449 | 104 |
| Eliquis | Apixaban | 440 | 59 |
| Lisinopril | Lisinopril | 428 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 364 | 79 |
| Alprazolam | Alprazolam | 363 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 337 | 44 |
| Tramadol Hcl | Tramadol Hcl | 335 | 85 |
| Trazodone Hcl | Trazodone Hcl | 330 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 324 | 82 |
| Losartan Potassium | Losartan Potassium | 313 | 71 |
| Omeprazole | Omeprazole | 298 | 79 |
| Carvedilol | Carvedilol | 279 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 67 |
| Potassium Chloride | Potassium Chloride | 273 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 258 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 239 | 43 |
| Xarelto | Rivaroxaban | 232 | 31 |
| Donepezil Hcl | Donepezil Hcl | 219 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 207 | 44 |
| Levetiracetam | Levetiracetam | 191 | 24 |
| Simvastatin | Simvastatin | 186 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 44 |
| Sertraline Hcl | Sertraline Hcl | 170 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 29 |
| Morphine Sulfate Er | Morphine Sulfate | 161 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 64 |
| Famotidine | Famotidine | 154 | 33 |
| Ibuprofen | Ibuprofen | 150 | 50 |
| Montelukast Sodium | Montelukast Sodium | 148 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 145 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 35 |
| Ozempic | Semaglutide | 138 | 24 |
| Memantine Hcl | Memantine Hcl | 127 | 19 |
| Temazepam | Temazepam | 127 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 127 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 32 |
| Latanoprost | Latanoprost | 126 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 45 |
| Azithromycin | Azithromycin | 114 | 86 |
| Trulicity | Dulaglutide | 113 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 111 | 17 |
| Nifedipine Er | Nifedipine | 107 | 30 |
| Lorazepam | Lorazepam | 104 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 75 |
| Diazepam | Diazepam | 103 | 18 |
| Buspirone Hcl | Buspirone Hcl | 100 | 17 |
| Atenolol | Atenolol | 99 | 17 |
| Jardiance | Empagliflozin | 96 | 19 |
| Mirtazapine | Mirtazapine | 96 | 27 |
| Glimepiride | Glimepiride | 95 | 26 |
| Spironolactone | Spironolactone | 94 | 21 |
| Allopurinol | Allopurinol | 93 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 13 |
| Clonidine Hcl | Clonidine Hcl | 90 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 25 |
| Methylprednisolone | Methylprednisolone | 90 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 15 |
| Glipizide | Glipizide | 88 | 16 |
| Meloxicam | Meloxicam | 87 | 23 |
| Methadone Hcl | Methadone Hcl | 86 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 82 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 80 | 17 |
| Clonazepam | Clonazepam | 79 | 15 |
| Amoxicillin | Amoxicillin | 78 | 51 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 38 |
| Finasteride | Finasteride | 73 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 54 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 72 | 40 |
| Hydromorphone Hcl | Hydromorphone Hcl | 72 | suppressed |
| Lactulose | Lactulose | 72 | 23 |
| Mupirocin | Mupirocin | 71 | 38 |
| Alendronate Sodium | Alendronate Sodium | 69 | 17 |
| Cephalexin | Cephalexin | 68 | 37 |
| Lovastatin | Lovastatin | 67 | 19 |
| Naproxen | Naproxen | 66 | 39 |
| Novolog Flexpen | Insulin Aspart | 66 | 13 |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Ondansetron Odt | Ondansetron | 64 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 61 | 12 |
| Midodrine Hcl | Midodrine Hcl | 60 | 16 |
| Prednisone | Prednisone | 60 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 17 |
| Megestrol Acetate | Megestrol Acetate | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 18 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 34 |
| Sucralfate | Sucralfate | 51 | suppressed |
| Baclofen | Baclofen | 50 | 11 |
| Admelog Solostar | Insulin Lispro | 49 | suppressed |
| Dexamethasone | Dexamethasone | 49 | 40 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Hydrocortisone | Hydrocortisone | 48 | 15 |
| Linzess | Linaclotide | 48 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 21 |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 27 |
| Oxcarbazepine | Oxcarbazepine | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Valsartan | Valsartan | 45 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | 23 |
| Bumetanide | Bumetanide | 42 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 12 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 18 |
| Levofloxacin | Levofloxacin | 39 | 21 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Nystatin | Nystatin | 32 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Glucagon Emergency Kit | Glucagon | 29 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | 11 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Darunavir | Darunavir | 25 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 12 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Permethrin | Permethrin | 21 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | 16 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Daptomycin | Daptomycin | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Xadago | Safinamide Mesylate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ritonavir | Ritonavir | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $854.88 · 30 records | ACADIA Pharmaceuticals Inc | AFREZZA, AREXVY, Briviact, CAPLYTA, Cologuard Collection Kit, DAYBUE, ELIQUIS, JARDIANCE, NALOCET, Nayzilam, Ozempic, PROLATE, REXULTI, Rybelsus, SHINGRIX, TANLOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VALTOCO, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error